Bolt Biotherapeutics faces a precarious financial outlook characterized by a rapid depletion of its asset base, which has fallen from $159.8 million in 2023Q4 to $48.0 million in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$4.57-34.8% vs -$3.39 | $5,000-99.0% vs $500,000 |
Q2 2026 May 12, 2026 | -$4.31-51.2% vs -$2.85 | $26,000-98.3% vs $2M |
Q2 2026 Mar 12, 2026 | -$3.84+10.7% vs -$4.30 | $3M+275.0% vs $666,667 |
Q4 2025 Nov 12, 2025 | -$3.72+26.6% vs -$5.07 | $2M+164.3% vs $820,800 |
REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences.
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned.
Shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.20 and traded as high as $4.48. Bolt Biotherapeutics shares last traded at $4.14, with a volume of 34,467 shares trading hands. Wall
Benchmark BOLT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bolt Biotherapeutics, Inc. (BOLT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.54 | $12.57M | -0.38 | 0.07% | -611.47% | -126.23% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $9.54 | $845.34M | -4.09 | 627.84% | -72.38% | -804.38% | — |
Bolt Biotherapeutics, Inc. (BOLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bolt Biotherapeutics, Inc. (BOLT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 11, 2026·SEC
May 12, 2026·SEC
Get notified when BOLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bolt Biotherapeutics, Inc. (BOLT) stock FAQ — growth, dividends, profitability & financials explained
Bolt Biotherapeutics, Inc. (BOLT) reported $4.7M in revenue over the trailing twelve months. Revenue was $7.7M in fiscal year 2025.
Bolt Biotherapeutics, Inc. (BOLT) grew revenue by 12.8% over the trailing twelve months, compared with the twelve months before.
No. Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $28.7M over the trailing twelve months.
Bolt Biotherapeutics, Inc. (BOLT) had a return on equity (ROE) of -126.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $31.5M over the trailing twelve months.
